Clinical trials located in

Zawadzkie

Zawadzkie city is located in Poland. Currently, 6 clinical trials are being conducted in this city.

Zawadzkie, a quaint town in Poland, is nestled in the Opole Voivodeship. Established in the 13th century, it boasts a rich history intertwined with coal mining, which significantly shaped its development. The town is named after the Zawadzkie family, who were instrumental in its early growth. A notable landmark is the St. Anne Church, a testament to its architectural heritage. Zawadzkie also prides itself on its picturesque landscapes, including the nearby Lubliniec Forest, offering a glimpse into the region’s natural beauty.

  • CT-EU-00057580

    Studying camlipixant for chronic cough treatment

    This study involves a year-long study of a drug known as Camlipixant (BLU-5937). The aim is to evaluate its potential effectiveness in treating persistent cough in adults who have not found relief with alternative treatments. The methodology involves giving Camlipixant (BLU-5937) to some participants and a placebo to others. The allocation of the real drug or placebo is not disclosed to all study participants. After 12 weeks of taking Camlipixant, your daily cough frequency will be assessed. The purpose of this evaluation is to determine whether it has a noticeable effect. Additionally, participants will be asked to self-assess the severity of their cough on a scale. Finally, participants will be asked to complete a survey detailing the impact of cough on everyday life, emotional well-being and interpersonal relationships.

    • Camlipixant/BLU-5937
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Evaluating depemokimab’s efficacy in severe asthma treatment

    This trial studies the long-term effects of depemokimab in adults and adolescents with severe eosinophilic asthma. Participants who previously joined specific depemokimab studies (206713 or 213744) continue treatment to assess long-term safety and efficacy. The trial monitors adverse events and checks for anti-drug antibodies to evaluate the drug’s sustained effectiveness. The study aims to ensure the safety and prolonged benefit of depemokimab for severe asthma management. It is vital for advancing asthma treatment and improving patient quality of life.

    • GSK3511294 (Depemokimab)
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Poland:

.